Ascentage Pharma Group International Announces Board and Committee Changes
The Board further announces that, with effect from June 7, 2024, the composition of the following Board committees will be changed as follows: Audit Committee: Dr. Yin will cease to be a member and Mr. Ren Wei will be appointed as a member in place of Dr. Yin. Remuneration Committee: Dr. Yin will cease to be the chairman and Mr. Ren Wei (an independent non-executive Director and an existing member) will be appointed as the chairman in place of Dr. Yin. Mr. Ye Changqing (an independent non-executive Director) will be appointed as a member. Nomination committee of the Company: Mr. Ye Changqing will cease to be a member and Dr. David Sidransky (an independent non-executive Director) will be appointed as a member in place of Mr. Ye Changqing.